Generali Investments Management Co LLC Purchases Shares of 11,855 Gilead Sciences, Inc. (NASDAQ:GILD)

Generali Investments Management Co LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 11,855 shares of the biopharmaceutical company's stock, valued at approximately $1,095,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC increased its stake in Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP increased its stake in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. Pacer Advisors Inc. increased its stake in Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock worth $594,370,000 after acquiring an additional 5,653,075 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $207,340,000. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock worth $193,274,000 after purchasing an additional 1,793,145 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Remove Ads

Gilead Sciences Stock Performance

Shares of GILD stock traded up $1.21 on Friday, reaching $107.08. The stock had a trading volume of 26,496,292 shares, compared to its average volume of 6,793,320. The stock has a market cap of $133.35 billion, a P/E ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a 50 day simple moving average of $103.68 and a 200 day simple moving average of $93.85.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. Gilead Sciences's payout ratio is 854.05%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Morgan Stanley increased their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, March 11th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $104.52.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.29% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.